CHUGAI PHARMACEUTICAL CO., LTD.

Print

Translation

Mar 28, 2018

Name of listed company:   Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Tatsuro Kosaka
Inquiries to: Masahiko Uchida, General Manager,
Corporate Communications Dept.
  Tel: +81-(0)3-3273-0881

Favorable Ruling in Patent Infringement Lawsuit Relating to Emicizumab

Chugai Pharmaceutical Co., Ltd. announces that a ruling in favor of Chugai has been rendered in the lawsuit relating to Chugai’s new drug emicizumab at the Tokyo District Court as follows.

  1. History
    Service of Complaint May 6, 2016
    Judgment March 28, 2018
  2. Reasons and Background for the Action
    It is alleged by Baxalta that Chugai’s new drug (pending the National Health Insurance price listing) for the treatment of hemophilia A, emicizumab (development code: ACE910), infringes Baxalta’s patent (patent number 4313531) and thus it filed for an injunction against manufacture, usage, transfer, exportation, and offer of any transfer regarding emicizumab, and requested cessation.
    Tokyo District Court rendered a decision in favor of Chugai's claim.
  3. Party Who Filed the Complaint
    (1) Name: Baxalta Incorporated
    Baxalta GmbH
    (2) Address: 1200 Lakeside Drive Bannockburn, IL 60015, USA
    Thurganerstrasse 130 Glattpark Opfikon 8152, Switzerland
  4. Contents of the Ruling
    (1)  Baxalta’s claim shall be dismissed in its entirety.
    (2)  Court costs shall be borne by Baxalta.
  5. Prospects
    No changes are expected in Chugai’s financial prospects.

Contact:
For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp

For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

[ PDF 17KB]

To view PDF files,
you will need Adobe® Reader® which is available as a free download.

Close